Cue Biopharma, Inc.

NasdaqCM:CUE Stok Raporu

Piyasa değeri: US$64.6m

Cue Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Cue Biopharma CEO'su Dan Passeri, Aug2016 tarihinde atandı, in görev süresi 8.25 yıldır. in toplam yıllık tazminatı $ 3.02M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.1% maaş ve 79.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.21% ine doğrudan sahiptir ve bu hisseler $ 137.27K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.5 yıl ve 6.3 yıldır.

Anahtar bilgiler

Dan Passeri

İcra Kurulu Başkanı

US$3.0m

Toplam tazminat

CEO maaş yüzdesi20.1%
CEO görev süresi8.3yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi6.5yrs
Yönetim Kurulu ortalama görev süresi6.3yrs

Son yönetim güncellemeleri

Recent updates

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10
Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18
Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12
Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19
Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04
We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

CEO Tazminat Analizi

Dan Passeri'un ücretlendirmesi Cue Biopharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$47m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$3mUS$605k

-US$51m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$1mUS$748k

-US$53m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$2mUS$531k

-US$44m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$6mUS$501k

-US$45m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$395k

-US$37m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$45m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$834kUS$345k

-US$39m

Sep 30 2018n/an/a

-US$38m

Jun 30 2018n/an/a

-US$30m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$410kUS$325k

-US$23m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 3.02M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Dan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Dan Passeri (63 yo)

8.3yrs

Görev süresi

US$3,015,480

Tazminat

Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Daniel Passeri
CEO & Director8.3yrsUS$3.02m0.21%
$ 137.3k
Anish Suri
President & Chief Scientific Officer6.5yrsUS$1.21m0.21%
$ 138.4k
Kerri-Ann Millar
Chief Financial Officer6.5yrsUS$1.16m0.023%
$ 14.6k
Ronald Seidel
Co-Founderno dataUS$316.63kVeri yok
Rodolfo Chaparro
Co-Founder & Senior Advisorno dataUS$316.63kVeri yok
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Boardno dataVeri yokVeri yok
Colin Sandercock
Senior VP6.9yrsUS$625.51kVeri yok
Matteo Levisetti
Chief Medical Officer3.8yrsVeri yokVeri yok
Lucinda Warren
Chief Business Officerless than a yearVeri yokVeri yok

6.5yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: CUE 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Daniel Passeri
CEO & Director8.3yrsUS$3.02m0.21%
$ 137.3k
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Board9.8yrsVeri yokVeri yok
Frederick Driscoll
Independent Director6.4yrsUS$76.31k0%
$ 0
Frank Morich
Independent Chairman of the Board6.3yrsUS$106.27k0.044%
$ 28.6k
Peter Kiener
Independent Director8.7yrsUS$144.18k0.00056%
$ 361.9
Hidde L. Ploegh
Member of Scientific & Clinical Advisory Boardno dataVeri yokVeri yok
Rafi Ahmed
Member of Scientific Advisory Board1.8yrsVeri yokVeri yok
Kenneth Pienta
Clinical Advisor1.8yrsVeri yokVeri yok
Patrick Verheyen
Independent Director1.6yrsUS$135.31k0.013%
$ 8.3k
Abul K. Abbas
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
Karolina Palucka
Member of Scientific & Clinical Advisory Board7.8yrsVeri yokVeri yok
Michael Kalos
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok

6.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CUE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).